Loyola University Medical Center

Gottlieb Memorial Hospital

MacNeal Hospital

Back to homepage
myLoyola
Used as main image by Phynd in search results and profile page

Robert C Flanigan, MD

Urology, Surgery, General

Provider Ratings

4.9 out of 5 (52 ratings)

Provider Groups

  • Loyola Medicine Physician

  • Loyola Physician Partners

Primary Contact

888-584-7888
Provider Groups

  • Loyola Medicine Physician

  • Loyola Physician Partners

Primary Contact
888-584-7888
Print Share

Services & Specialties

Areas of Specialization

  • Surgery, General
  • Urology

Locations & Contact

Primary Location

Fahey Center

2160 S 1st Ave
Maywood , IL 60160

(888)584-7888 View Details

About

Academic Title

Professor

Ages Seen

Adults - Over 65
Adults - 18 to 64

Additional Resources

Education & Certifications

Education

Education:
Case Western Reserve University School of Medicine (1972)

Internship:
Case Western Reserve University (1973)

Internship:
Case Western Reserve University/ University Hospitals Case Medical Center (1973)

Internship:
Case Western Reserve University/ University Hospitals Case Medical Center (1973)

Internship:
Case Western Reserve University/ University Hospitals Cleveland Medical Center (1973)

Residency:
Case Western Reserve University (1978)

Residency:
Case Western Reserve University/ University Hospitals Case Medical Center (1978)

Residency:
Case Western Reserve University/ University Hospitals Cleveland Medical Center (1978)

Board Certifications

Urology, Urology, American Board of (1980)

Provider Groups

Loyola Medicine Physician

Loyola Physician Partners

Provider Ratings

The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn More >

4.9 out of 5

(52 ratings)

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

13 Reviews

08/21/2024

Love my care at Loyola

05/30/2024

Excellent medical care

04/29/2024

First time I’ve seen him and what I was expecting so far I understand he was very helpful way he explained the options.

04/25/2024

Excellent

02/29/2024

Dr. Flanigan is the best.

01/04/2024

Great now and over time

12/07/2023

Being treated as a person not just a number on a chart

11/30/2023

He's been my doctor for about 21 years, and is kind and caring.

10/14/2023

None

10/05/2023

Long term relationship with provider, always excellent truthful and human

09/27/2023

Couldn't be more pleased.

07/01/2023

Just a nice guy

07/01/2023

Excellent doctor !
Show more

Publications

  • Quantifying preserved renal volume and function in patients undergoing standard partial nephrectomy vs. tumor enucleation for localized renal tumors. Ellis, J. L.; Sontag-Milobsky, I.; Chen, V. S.; Rac, G.; Hartman, N. C.; Gorbonos, A.; Woods, M. E.; Flanigan, R. C.; Quek, M.; Patel, H. D.; Gupta, G. N.; Urologic oncology
  • A prospective evaluation of the prostate microbiome in malignant and benign tissue using transperineal biopsy. Chen, V. S.; James, C.; Khemmani, M.; Desai, S.; Doshi, C.; Rac, G.; Ellis, J. L.; Patel, H. D.; Barkan, G. A.; Gupta, G. N.; Flanigan, R. C.; Wolfe, A. J.; The Prostate
  • MRI at diagnostic versus confirmatory biopsy during MRI-based active surveillance of prostate cancer. Marras, M.; Ellis, J. L.; Copelan, O.; Naha, U.; Han, T.; Rac, G.; Quek, M. L.; Gorbonos, A.; Woods, M. E.; Flanigan, R. C.; Gupta, G. N.; Patel, H. D.; Urologic oncology
  • Variability in prostate cancer detection among radiologists and urologists using MRI fusion biopsy. Patel, H. D.; Halgrimson, W. R.; Sweigert, S. E.; Shea, S. M.; Turk, T. M. T.; Quek, M. L.; Gorbonos, A.; Flanigan, R. C.; Goldberg, A.; Gupta, G. N.; BJUI compass
  • Incidental Discovery of Hepatocellular Carcinoma on 18F-PSMA PET CT Performed for Prostate Cancer Reassessment. Hekman, L.; Napierkowski, E.; Hartman, N. C.; Ellis, J. L.; Wagner, R. H.; Bova, D.; Picken, M. M.; Flanigan, R. C.; Case reports in surgery
  • Neoadjuvant Chemotherapy Before Radical Cystectomy for Muscle-Invasive Bladder Cancer: Elective and Eligibility Factors Impacting Utilization. Patel, H. D.; Naha, U.; Chen, V. S.; Ko, C.; Yang, R.; Druck, A.; Rac, G.; Ellis, J. L.; Gupta, G. N.; Woods, M. E.; Gorbonos, A.; Flanigan, R.; Quek, M. L.; Urology practice
  • Impact of intravesical Bacillus Calmette-Guérin and chemotherapy on the bladder microbiome in patients with non-muscle invasive bladder cancer. James, C.; Gomez, K.; Desai, S.; Patel, H. D.; Rac, G.; Doshi, C. P.; Dornbier, R.; Bajic, P.; Halverson, T.; Gupta, G. N.; Quek, M. L.; Gorbonos, A.; Flanigan, R.; Wolfe, A. J.; Frontiers in cellular and infection microbiology
  • The rising incidence of ductal adenocarcinoma and intraductal carcinoma of the prostate: Diagnostic accuracy of biopsy, MRI-visibility, and outcomes. Pahouja, G.; Patel, H. D.; Desai, S.; Rac, G.; Cheng, T.; Okabe, Y.; Gorbonos, A.; Quek, M. L.; Flanigan, R. C.; Picken, M. M.; Gupta, G. N.; Urologic oncology
  • MRI versus non-MRI diagnostic pathways before radical prostatectomy: Impact on nerve-sparing, positive surgical margins, and biochemical recurrence. Patel, H. D.; Okabe, Y.; Rac, G.; Pahouja, G.; Desai, S.; Shea, S. M.; Gorbonos, A.; Quek, M. L.; Flanigan, R. C.; Goldberg, A.; Gupta, G. N.; Urologic oncology
  • MRI vs Transrectal Ultrasound to Estimate Prostate Volume and PSAD: Impact on Prostate Cancer Detection. Choe, S.; Patel, H. D.; Lanzotti, N.; Okabe, Y.; Rac, G.; Shea, S. M.; Gorbonos, A.; Quek, M. L.; Flanigan, R. C.; Goldberg, A.; Gupta, G. N.; Urology
  • A prostate biopsy risk calculator based on MRI: development and comparison of the Prospective Loyola University multiparametric MRI (PLUM) and Prostate Biopsy Collaborative Group (PBCG) risk calculators. Patel, H. D.; Koehne, E. L.; Shea, S. M.; Fang, A. M.; Gerena, M.; Gorbonos, A.; Quek, M. L.; Flanigan, R. C.; Goldberg, A.; Rais-Bahrami, S.; Gupta, G. N.; BJU international
  • Percentage of sarcomatoid histology is associated with survival in renal cell carcinoma: Stratification and implications by clinical metastatic stage. Patel, H. D.; Man, A.; Koehne, E. L.; Rac, G.; Aragao, A. P.; Flanigan, R. C.; Gorbonos, A.; Gupta, G. N.; Woods, M. E.; Picken, M. M.; Quek, M. L.; Urologic oncology
  • Health-Related Quality of Life and Toxicity After Definitive High-Dose-Rate Brachytherapy Among Veterans With Prostate Cancer. Harris, A. A.; Yasuda, M.; Wu, M. S.; Deirmenjian, J. M.; Farooq, A.; Baldea, K. G.; Flanigan, R.; Harkenrider, M. M.; Welsh, J. S.; Solanki, A. A.; Federal practitioner : for the health care professionals of the VA, DoD, and PHS
  • Systematic versus Targeted Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy among Men with Visible Lesions. Patel, H. D.; Koehne, E. L.; Shea, S. M.; Fang, A. M.; Gorbonos, A.; Quek, M. L.; Flanigan, R. C.; Goldberg, A.; Rais-Bahrami, S.; Gupta, G. N.; The Journal of urology
  • Risk of prostate cancer for men with prior negative biopsies undergoing magnetic resonance imaging compared with biopsy-naive men: A prospective evaluation of the PLUM cohort. Patel, H. D.; Koehne, E. L.; Shea, S. M.; Bhanji, Y.; Gerena, M.; Gorbonos, A.; Quek, M. L.; Flanigan, R. C.; Goldberg, A.; Gupta, G. N.; Cancer
  • African American Men have Increased Risk of Prostate Cancer Detection Despite Similar Rates of Anterior Prostatic Lesions and PI-RADS Grade on Multiparametric Magnetic Resonance Imaging. Patel, H. D.; Doshi, C. P.; Koehne, E. L.; Hart, S.; Van Kuiken, M.; Quek, M. L.; Flanigan, R. C.; Gupta, G. N.; Urology
  • Cytoreductive Nephrectomy for Synchronous Metastatic Renal Cell Carcinoma-Are There Any Favorable Risk Patients? Patel, H. D.; Clark, J. I.; Flanigan, R. C.; The Journal of urology
  • Re: Active Surveillance for Men with Intermediate Risk Prostate Cancer. Koehne, E. L.; Flanigan, R. C.; European urology
  • Patient and physician reported toxicity with two-fraction definitive high-dose-rate prostate brachytherapy: the impact of implant interval. Harris, A. A.; Korpics, M.; Sherwani, Z.; Farooq, A.; Baldea, K. G.; Flanigan, R.; Harkenrider, M. M.; Solanki, A. A.; Journal of contemporary brachytherapy
  • Penile Paget's Disease: A Case Report and Review of the Literature. Flanigan, R. C.; Dornbier, R.; Quek, M. L.; Woods, M.; Gorbonos, A.; Gupta, G.; Harkenrider, M. M.; Solanki, A.; Badami, A.; Henry, E.; Berg, S.; Bova, D.; Barkan, G. A.; Picken, M. M.; Archives of nephrology and urology
  • Thirty-day hospital revisits after prostate brachytherapy: who is at risk? Li, B.; Kirshenbaum, E. J.; Blackwell, R. H.; Gange, W. S.; Saluk, J.; Zapf, M. A. C.; Kothari, A. N.; Flanigan, R. C.; Gupta, G. N.; Prostate international
  • Lipofuscin pigmentation (so called "melanosis") of the bladder. Atieh, M.; McIntire, P. J.; Kilic, I.; Picken, M. M.; Flanigan, R. C.; Barkan, G. A.; Pambuccian, S. E.; Diagnostic cytopathology
  • Re: Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. Flanigan, R. C.; European urology
  • Role of Multiparametric Magnetic Resonance Imaging Prostate Specific Antigen Density and PI-RADS™ Score in Predicting Up Staging in Men on Active Surveillance. Van Kuiken, M.; Blackwell, R. H.; Bisanz, B.; Joyce, C.; Yacoub, J.; Shea, S.; Goldberg, A.; Quek, M. L.; Flanigan, R. C.; Gupta, G. N.; Urology practice
  • Pre-diagnostic carbohydrate intake and treatment failure after radical prostatectomy for early-stage prostate cancer. Kim, K.; Kong, A.; Flanigan, R. C.; Quek, M. L.; Hollowell, C. M. P.; Vidal, P. P.; Branch, J.; Dean, L. A.; Macias, V.; Kajadacsy-Balla, A. A.; Fitzgibbon, M. L.; Cintron, D.; Liu, L.; Freeman, V. L.; Cancer causes & control : CCC
  • Transitioning From a Low-Dose-Rate to a High-Dose-Rate Prostate Brachytherapy Program: Comparing Initial Dosimetry and Improving Workflow Efficiency Through Targeted Interventions. Solanki, A. A.; Mysz, M. L.; Patel, R.; Surucu, M.; Kang, H.; Plypoo, A.; Bajaj, A.; Korpics, M.; Martin, B.; Hentz, C.; Gupta, G.; Farooq, A.; Baldea, K. G.; Pawlowski, J.; Roeske, J.; Flanigan, R.; Small, W.; Harkenrider, M. M.; Advances in radiation oncology
  • Socioeconomic Disparities in the Acute Management of Stone Disease in the United States. Kirshenbaum, E. J.; Doshi, C.; Dornbier, R.; Blackwell, R. H.; Bajic, P.; Gupta, G. N.; Gorbonos, A.; Turk, T. M. T.; Flanigan, R. C.; Baldea, K. G.; Journal of endourology
  • The LACE Score as a Tool to Identify Radical Cystectomy Patients at Increased Risk of 90-Day Readmission and Mortality. Saluk, J. L.; Blackwell, R. H.; Gange, W. S.; Zapf, M. A. C.; Kothari, A. N.; Kuo, P. C.; Quek, M. L.; Flanigan, R. C.; Gupta, G. N.; Current urology
  • Sunitinib and Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma. Bajic, P.; Flanigan, R. C.; Joyce, C. J.; Clark, J. I.; The Journal of urology
  • Adhesive Bowel Obstruction Following Urologic Surgery: Improved Outcomes with Early Intervention. Blackwell, R. H.; Kothari, A. N.; Shah, A.; Gange, W.; Quek, M. L.; Luchette, F. A.; Flanigan, R. C.; Kuo, P. C.; Gupta, G. N.; Current urology
  • Diversity of the midstream urine microbiome in adults with chronic kidney disease. Kramer, H.; Kuffel, G.; Thomas-White, K.; Wolfe, A. J.; Vellanki, K.; Leehey, D. J.; Bansal, V. K.; Brubaker, L.; Flanigan, R.; Koval, J.; Wadhwa, A.; Zilliox, M. J.; International urology and nephrology
  • Implications of postoperative pulmonary aspiration following major urologic surgery. Kirshenbaum, E. J.; Blackwell, R. H.; Li, B.; Kothari, A. N.; Kuo, P. C.; Flanigan, R. C.; Gorbonos, A.; Gupta, G. N.; The Canadian journal of urology
  • Examining Patient Willingness to Pay for Magnetic Resonance Imaging Guided Prostate Biopsy: Implications in the Era of Health Savings Accounts. Ellimoottil, C.; Marcotte, M.; Grace, D.; Krasnikov, A.; Phillips, J. M.; Quek, M. L.; Flanigan, R.; Gupta, G. N.; Urology practice
  • Incidence of Adverse Contrast Reaction Following Nonintravenous Urinary Tract Imaging. Blackwell, R. H.; Kirshenbaum, E. J.; Zapf, M. A. C.; Kothari, A. N.; Kuo, P. C.; Flanigan, R. C.; Gupta, G. N.; European urology focus
  • Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men. Catalona, W. J.; Richie, J. P.; Ahmann, F. R.; Hudson, M. A.; Scardino, P. T.; Flanigan, R. C.; DeKernion, J. B.; Ratliff, T. L.; Kavoussi, L. R.; Dalkin, B. L.; Waters, W. B.; MacFarlane, M. T.; Southwick, P. C.; The Journal of urology
  • Urinary incontinence and diuretic avoidance among adults with chronic kidney disease. Patel, M.; Vellanki, K.; Leehey, D. J.; Bansal, V. K.; Brubaker, L.; Flanigan, R.; Koval, J.; Wadhwa, A.; Balasubramanian, N.; Sandhu, J.; Kramer, H.; International urology and nephrology
  • PLK-1 Silencing in Bladder Cancer by siRNA Delivered With Exosomes. Greco, K. A.; Franzen, C. A.; Foreman, K. E.; Flanigan, R. C.; Kuo, P. C.; Gupta, G. N.; Urology
  • Early Intervention during Acute Stone Admissions: Revealing "The Weekend Effect" in Urological Practice. Blackwell, R. H.; Barton, G. J.; Kothari, A. N.; Zapf, M. A.; Flanigan, R. C.; Kuo, P. C.; Gupta, G. N.; The Journal of urology
  • Urinary Exosomes: The Potential for Biomarker Utility, Intercellular Signaling and Therapeutics in Urological Malignancy. Franzen, C. A.; Blackwell, R. H.; Foreman, K. E.; Kuo, P. C.; Flanigan, R. C.; Gupta, G. N.; The Journal of urology
  • Long-term Incidence of Hematuria, Urethral Stricture and Bladder Cancer after Radiation Therapy for Prostate Cancer. Blackwell, R. H.; Kandabarow, A. M.; Gupta, G. N.; Harkenrider, M. M.; Quek, M. L.; Flanigan, R. C.; Urology practice
  • Urothelial cells undergo epithelial-to-mesenchymal transition after exposure to muscle invasive bladder cancer exosomes. Franzen, C. A.; Blackwell, R. H.; Todorovic, V.; Greco, K. A.; Foreman, K. E.; Flanigan, R. C.; Kuo, P. C.; Gupta, G. N.; Oncogenesis
  • Postoperative Atrial Fibrillation Predicts Long-Term Cardiovascular Events after Radical Cystectomy. Blackwell, R. H.; Ellimoottil, C.; Bajic, P.; Kothari, A.; Zapf, M.; Kliethermes, S.; Flanigan, R. C.; Quek, M. L.; Kuo, P. C.; Gupta, G. N.; The Journal of urology
  • A primer on clinical trial design. Ellimoottil, C.; Vijan, S.; Flanigan, R. C.; Urologic oncology
  • New modalities for evaluation and surveillance of complex renal cysts. Ellimoottil, C.; Greco, K. A.; Hart, S.; Patel, T.; Sheikh, M. M.; Turk, T. M.; Flanigan, R. C.; The Journal of urology
  • Seeking a standard for adequate pathologic lymph node staging in primary bladder carcinoma. Wang, L.; Mudaliar, K.; Mehta, V.; Barkan, G. A.; Quek, M. L.; Flanigan, R. C.; Picken, M. M.; Virchows Archiv : an international journal of pathology
  • Legends in urology. Flanigan, R. C.; The Canadian journal of urology
  • Radical Cystectomy after BCG Immunotherapy for High-Risk Nonmuscle-Invasive Bladder Cancer in Patients with Previous Prostate Radiotherapy. Rao, M. V.; Quek, M. L.; Jayram, G.; Ellimoottil, C.; Sondej, T.; Hugen, C. M.; Flanigan, R. C.; Steinberg, G. D.; ISRN urology
  • Renal lymph nodes for tumor staging: appraisal of 871 nephrectomies with examination of hilar fat. Mehta, V.; Mudaliar, K.; Ghai, R.; Quek, M. L.; Milner, J.; Flanigan, R. C.; Picken, M. M.; Archives of pathology & laboratory medicine
  • An analysis of leukapheresis and central venous catheter use in the randomized, placebo controlled, phase 3 IMPACT trial of Sipuleucel-T for metastatic castrate resistant prostate cancer. Flanigan, R. C.; Polcari, A. J.; Shore, N. D.; Price, T. H.; Sims, R. B.; Maher, J. C.; Whitmore, J. B.; Corman, J. M.; The Journal of urology
  • Predictors of Gleason Score (GS) upgrading on subsequent prostatectomy: a single Institution study in a cohort of patients with GS 6. Mehta, V.; Rycyna, K.; Baesens, B. M.; Barkan, G. A.; Paner, G. P.; Flanigan, R. C.; Wojcik, E. M.; Venkataraman, G.; International journal of clinical and experimental pathology
  • Intravesical bacillus Calmette-Guerin immunotherapy after previous prostate radiotherapy for high-grade non-muscle-invasive bladder cancer. Rao, M. V.; Ellimoottil, C.; Sondej, T.; Flanigan, R. C.; Quek, M. L.; Urologic oncology
  • Prognostic variables and nomograms for renal cell carcinoma. Flanigan, R. C.; Polcari, A. J.; Hugen, C. M.; International journal of urology : official journal of the Japanese Urological Association
  • Risk factors for recurrence following radical cystectomy for pathologic node negative bladder cancer. Hugen, C. M.; Polcari, A. J.; Fitzgerald, M. P.; Dauw, C.; Flanigan, R. C.; Quek, M. L.; Journal of surgical oncology
  • Long-term outcomes of salvage radiotherapy for PSA-recurrent prostate cancer: validation of the Stephenson nomogram. Hugen, C. M.; Polcari, A. J.; Quek, M. L.; Garza, R. P.; Fitzgerald, M. P.; Flanigan, R. C.; World journal of urology
  • Comparison of open and robot-assisted pelvic lymphadenectomy for prostate cancer. Polcari, A. J.; Hugen, C. M.; Sivarajan, G.; Woods, M. E.; Paner, G. P.; Flanigan, R. C.; Quek, M. L.; Journal of endourology
  • Words of wisdom. Re: Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. Flanigan, R. C.; Polcari, A.; European urology
  • The role of cytoreductive nephrectomy in the era of molecular targeted therapy. Polcari, A. J.; Gorbonos, A.; Milner, J. E.; Flanigan, R. C.; International journal of urology : official journal of the Japanese Urological Association
  • The role of lymph node density in bladder cancer prognostication. Quek, M. L.; Flanigan, R. C.; World journal of urology
  • Morphometric signature differences in nuclei of Gleason pattern 4 areas in Gleason 7 prostate cancer with differing primary grades on needle biopsy. Venkataraman, G.; Rycyna, K.; Rabanser, A.; Heinze, G.; Baesens, B. M.; Ananthanarayanan, V.; Paner, G. P.; Barkan, G. A.; Flanigan, R. C.; Wojcik, E. M.; The Journal of urology
  • Renal cell carcinoma in two patients with crossed fused ectopic kidneys. Davis, C. M.; Rao, M. V.; Flanigan, R. C.; Quek, M. L.; Urologia internationalis
  • An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Wood, C.; Srivastava, P.; Bukowski, R.; Lacombe, L.; Gorelov, A. I.; Gorelov, S.; Mulders, P.; Zielinski, H.; Hoos, A.; Teofilovici, F.; Isakov, L.; Flanigan, R.; Figlin, R.; Gupta, R.; Escudier, B.; C-100-12 RCC Study Group; Lancet (London, England)
  • Renal FNA-based typing of renal masses remains a useful adjunctive modality: evaluation of 31 renal masses with correlative histology. Masoom, S.; Venkataraman, G.; Jensen, J.; Flanigan, R. C.; Wojcik, E. M.; Cytopathology : official journal of the British Society for Clinical Cytology
  • The importance of histology and cytogenetics in decision making for renal cell carcinoma. Garcia, J. G.; Picken, M. M.; Flanigan, R. C.; World journal of urology
  • Chromosome 1 analysis in chromophobe renal cell carcinomas with tissue microarray (TMA)-facilitated fluorescence in situ hybridization (FISH) demonstrates loss of 1p/1 which is also present in renal oncocytomas. Meyer, P. N.; Cao, Y.; Jacobson, K.; Krausz, T.; Flanigan, R. C.; Picken, M. M.; Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • Analysis of chromosome 1p abnormalities in renal oncocytomas by loss of heterozygosity studies: correlation with conventional cytogenetics and fluorescence in situ hybridization. Picken, M. M.; Chyna, B.; Flanigan, R. C.; Lee, J. M.; American journal of clinical pathology
  • Validation of World Health Organization/International Society of Urologic Pathology 2004 classification schema for bladder urothelial carcinomas using quantitative nuclear morphometry: identification of predictive features using bootstrap method. Kapur, U.; Antic, T.; Venkataraman, G.; Durazo-Arvizu, R.; Quek, M. M.; Flanigan, R. C.; Wojcik, E. M.; Urology
  • Identification of patients with low-risk for aneuploidy: comparative discriminatory models using linear and machine-learning classifiers in prostate cancer. Venkataraman, G.; Heinze, G.; Holmes, E. W.; Ananthanarayanan, V.; Bostwick, D. G.; Paner, G. P.; Bradford-De La garza, C. M.; Brown, H. G.; Flanigan, R. C.; Wojcik, E. M.; The Prostate
  • Renal tumors: the good, the bad, and the ugly. Flanigan, R. C.; International journal of urology : official journal of the Japanese Urological Association
  • Xp11.2 translocation renal cell carcinoma with very aggressive course in five adults. Meyer, P. N.; Clark, J. I.; Flanigan, R. C.; Picken, M. M.; American journal of clinical pathology
  • Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer. Nagda, S. N.; Mohideen, N.; Lo, S. S.; Khan, U.; Dillehay, G.; Wagner, R.; Campbell, S.; Flanigan, R.; International journal of radiation oncology, biology, physics
  • High incidence of chromosome 1 abnormalities in a series of 27 renal oncocytomas: cytogenetic and fluorescence in situ hybridization studies. Paner, G. P.; Lindgren, V.; Jacobson, K.; Harrison, K.; Cao, Y.; Campbell, S. C.; Flanigan, R. C.; Picken, M. M.; Archives of pathology & laboratory medicine
  • Urothelial-cell carcinoma and solitary kidney: outcomes with renal-sparing management. Milner, J. E.; Voelzke, B. B.; Flanigan, R. C.; Sharma, S. K.; Perry, K. T.; Turk, T. M.; Journal of endourology
  • Radical cystectomy with extended lymphadenectomy in the presence of a pelvic kidney. Quek, M. L.; Basrawala, Z.; McClung, C.; Flanigan, R. C.; Urology
  • Morphometric sum optical density as a surrogate marker for ploidy status in prostate cancer: an analysis in 180 biopsies using logistic regression and binary recursive partitioning. Venkataraman, G.; Ananthanarayanan, V.; Paner, G. P.; He, R.; Masoom, S.; Sinacore, J.; Flanigan, R. C.; Wojcik, E. M.; Virchows Archiv : an international journal of pathology
  • Does lymphadenectomy improve cancer-specific survival in patients with renal cell carcinoma? Flanigan, R. C.; Nature clinical practice. Urology
  • Risk assessment for occult malignancy in the prostate before radical cystectomy. Kefer, J. C.; Voelzke, B. B.; Flanigan, R. C.; Wojcik, E. M.; Waters, W. B.; Campbell, S. C.; Urology
  • Androgen receptor levels are increased by interferons in human prostate stromal and epithelial cells. Basrawala, Z.; Alimirah, F.; Xin, H.; Mohideen, N.; Campbell, S. C.; Flanigan, R. C.; Choubey, D.; Oncogene
  • The utility of screening renal ultrasonography: identifying renal cell carcinoma in an elderly asymptomatic population. Malaeb, B. S.; Martin, D. J.; Littooy, F. N.; Lotan, Y.; Waters, W. B.; Flanigan, R. C.; Koeneman, K. S.; BJU international
  • Renal neoplasms in younger adults: analysis of 112 tumors from a single institution according to the new 2004 World Health Organization classification and 2002 American Joint Committee on Cancer Staging System. Cao, Y.; Paner, G. P.; Perry, K. T.; Flanigan, R. C.; Campbell, S. C.; Picken, M. M.; Archives of pathology & laboratory medicine
  • Debulking nephrectomy in metastatic renal cancer. Flanigan, R. C.; Clinical cancer research : an official journal of the American Association for Cancer Research
  • Cytologic features of recurrent lymphoma involving the urinary bladder. Quinn, A. M.; Flanigan, R.; Sienko, A.; Wojcik, E. M.; Diagnostic cytopathology
  • Metastatic juxtaglomerular cell tumor in a 52-year-old man. Duan, X.; Bruneval, P.; Hammadeh, R.; Fresco, R.; Eble, J. N.; Clark, J. I.; Vigneswaran, W. T.; Flanigan, R. C.; Picken, M. M.; The American journal of surgical pathology
  • Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. Flanigan, R. C.; Mickisch, G.; Sylvester, R.; Tangen, C.; Van Poppel, H.; Crawford, E. D.; The Journal of urology
  • Pathologic quiz case: renal mass in an otherwise healthy man. Epithelioid angiomyolipoma. Rubinas, T. C.; Flanigan, R. C.; Picken, M. M.; Archives of pathology & laboratory medicine
  • Role of nephrectomy in metastatic kidney cancer. Yonover, P. M.; Sharma, S. K.; Flanigan, R. C.; Cancer treatment and research
  • Metastatic renal cell carcinoma. Flanigan, R. C.; Campbell, S. C.; Clark, J. I.; Picken, M. M.; Current treatment options in oncology
  • Nephrectomy in metastatic renal cell carcinoma. Campbell, S. C.; Flanigan, R. C.; Clark, J. I.; Current treatment options in oncology
  • Cytoreductive nephrectomy in metastatic renal cancer. Flanigan, R. C.; Current urology reports
  • Effect of prostatic edema on CT-based postimplant dosimetry. Dogan, N.; Mohideen, N.; Glasgow, G. P.; Keys, K.; Flanigan, R. C.; International journal of radiation oncology, biology, physics
  • Erectile dysfunction after radical prostatectomy: hemodynamic profiles and their correlation with the recovery of erectile function. Mulhall, J. P.; Slovick, R.; Hotaling, J.; Aviv, N.; Valenzuela, R.; Waters, W. B.; Flanigan, R. C.; The Journal of urology
  • Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. Flanigan, R. C.; Salmon, S. E.; Blumenstein, B. A.; Bearman, S. I.; Roy, V.; McGrath, P. C.; Caton, J. R.; Munshi, N.; Crawford, E. D.; The New England journal of medicine
  • T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Mercader, M.; Bodner, B. K.; Moser, M. T.; Kwon, P. S.; Park, E. S.; Manecke, R. G.; Ellis, T. M.; Wojcik, E. M.; Yang, D.; Flanigan, R. C.; Waters, W. B.; Kast, W. M.; Kwon, E. D.; Proceedings of the National Academy of Sciences of the United States of America
  • The role of resection for patients with renal carcinoma. Flanigan, R. C.; Yonover, P. M.; Current oncology reports
  • The role of radical nephrectomy in metastatic renal cell carcinoma. Flanigan, R. C.; Yonover, P. M.; Seminars in urologic oncology
  • Alterations in peripheral B cells and B cell progenitors following androgen ablation in mice. Ellis, T. M.; Moser, M. T.; Le, P. T.; Flanigan, R. C.; Kwon, E. D.; International immunology
  • Bacillus Calmette-Guerin. Is monthly maintenance an option for transitional cell carcinoma of the bladder? Flanigan, R. C.; DeLaurentis, D. A.; Waters, W. B.; Kunz, K.; Urologic oncology
  • The extent of biopsy involvement as an independent predictor of extraprostatic extension and surgical margin status in low risk prostate cancer: implications for treatment selection. Gao, X.; Mohideen, N.; Flanigan, R. C.; Waters, W. B.; Wojcik, E. M.; Leman, C. R.; The Journal of urology
  • Should radical nephrectomy be performed in the face of surgically incurable disease? Yonover, P. M.; Flanigan, R. C.; Current opinion in urology
  • Renal cell carcinoma with metastasis to the thyroid gland. Pitale, S. U.; Sizemore, G. W.; Bakhos, R.; DeJong, S. A.; Flanigan, R. C.; Emanuele, N. V.; Urologic oncology
  • Primary localized amyloidosis of the ureter and bladder managed by ileal interposition. Hafron, J. M.; Flanigan, R. C.; Techniques in urology
  • Comparative analysis of DNA flow cytometry and cytology of bladder washings: review of discordant cases. Bakhos, R.; Shankey, T. V.; Flanigan, R. C.; Fisher, S.; Wojcik, E. M.; Diagnostic cytopathology
  • Telomerase activity, telomere length, and DNA ploidy in prostatic intraepithelial neoplasia (PIN). Koeneman, K. S.; Pan, C. X.; Jin, J. K.; Pyle, J. M.; Flanigan, R. C.; Shankey, T. V.; Diaz, M. O.; The Journal of urology
  • Complications of prostate cryosurgery: CT findings in three patients. Kalbhen, C. L.; Salomon, C. G.; Dudiak, C. M.; Olson, M. C.; Flisak, M. E.; Flanigan, R. C.; Abdominal imaging
  • Prostate carcinoma: transrectal US after cryosurgical ablation. Salomon, C. G.; Kalbhen, C. L.; Dudiak, C. M.; Olson, M. C.; Flisak, M. E.; Flanigan, R. C.; Radiology
  • Efficacy of retrograde stentograms following cystectomy and diversion. Manion, S. P.; Waters, W. B.; Flanigan, R. C.; The Journal of urology
  • Role of surgery in patients with metastatic renal cell carcinoma. Flanigan, R. C.; Seminars in urologic oncology
  • Left renal vein hypertension as a cause of persistent gross hematuria. Challenger, R. J.; Dougherty, W. S.; Flisak, M. E.; Flanigan, R. C.; Urology
  • Limited efficacy of preoperative computed tomographic scanning for the evaluation of lymph node metastasis in patients before radical prostatectomy. Flanigan, R. C.; McKay, T. C.; Olson, M.; Shankey, T. V.; Pyle, J.; Waters, W. B.; Urology
  • Nephron-sparing surgery for renal cell carcinoma. Griffin, J. H.; Flanigan, R. C.; Techniques in urology
  • Transrectal ultrasound of the prostate bed after collagen injection. Salomon, C. G.; Dudiak, C. M.; Pyle, J. M.; Wheeler, J. S.; Waters, W. B.; Flanigan, R. C.; Journal of computer assisted tomography
  • What's new in urology. Flanigan, R. C.; Journal of the American College of Surgeons
  • DNA ploidy and proliferation heterogeneity in human prostate cancers. Shankey, T. V.; Jin, J. K.; Dougherty, S.; Flanigan, R. C.; Graham, S.; Pyle, J. M.; Cytometry
  • T1c cancer: what is it? Flanigan, R. C.; Dougherty, W. S.; Seminars in urologic oncology
  • Analysis of heterogeneity in human tumors: a unique role for flow and image cytometry? Shankey, T. V.; Jin, J. K.; Flanigan, R. C.; Pyle, J. M.; Cytometry
  • Parapubic hernia following radical retropubic prostatectomy. Norris, J. P.; Flanigan, R. C.; Pickleman, J.; Urology
  • Directed and random biopsies of the prostate: indications based on combined results of transrectal sonography and prostate-specific antigen density determinations. Olson, M. C.; Posniak, H. V.; Fisher, S. G.; Flisak, M. E.; Salomon, C. G.; Flanigan, R. C.; Waters, W. B.; Pyle, J. M.; AJR. American journal of roentgenology
  • Accuracy of digital rectal examination and transrectal ultrasonography in localizing prostate cancer. Flanigan, R. C.; Catalona, W. J.; Richie, J. P.; Ahmann, F. R.; Hudson, M. A.; Scardino, P. T.; DeKernion, J. B.; Ratliff, T. L.; Kavoussi, L. R.; Dalkin, B. L.; Waters, W. B.; MacFarlane, M. T.; Southwick, P. C.; The Journal of urology
  • Phase II evaluation of merbarone in renal cell carcinoma. Flanigan, R. C.; Saiers, J. H.; Wolf, M.; Kraut, E. H.; Smith, A. Y.; Blumenstein, B.; Crawford, E. D.; Investigational new drugs
  • Radical prostatectomy: transrectal sonographic evaluation to assess for local recurrence. Salomon, C. G.; Flisak, M. E.; Olson, M. C.; Dudiak, C. M.; Flanigan, R. C.; Waters, W. B.; Radiology
  • Prostatic cystic epithelial-stromal tumors: a report of 2 new cases. Kevwitch, M. K.; Walloch, J. L.; Waters, W. B.; Flanigan, R. C.; The Journal of urology
  • Oxidative tryptophan metabolism in renal allograft recipients: increased kynurenine synthesis is associated with inflammation and OKT3 therapy. Holmes, E. W.; Russell, P. M.; Kinzler, G. J.; Reckard, C. R.; Flanigan, R. C.; Thompson, K. D.; Bermes, E. W.; Cytokine
  • Female urethral diverticular with clear cell adenocarcinoma. Wheeler, J. S.; Flanigan, R. C.; Hong, H. Y.; Walloch, J. L.; Journal of surgical oncology
  • Free amino acids during chronic cyclosporine A toxicity in intact and partially nephrectomized rats. Holmes, E. W.; Kinzler, G. J.; Flanigan, R. C.; Bermes, E. W.; Experimental and molecular pathology
  • Ureteral stump carcinoma incidentally found at cystectomy for bladder cancer. Kinzler, G. J.; Wheeler, J. S.; Culkin, D. J.; Bowers, S.; Flanigan, R. C.; Urology
  • The effect of chronic renal insufficiency on cyclosporine nephrotoxicity. Kinzler, G. J.; Holmes, E. W.; Reckard, C. R.; Jablokow, V. R.; Fresco, R.; Flanigan, R. C.; The Journal of urology
  • Female urinary retention. Wheeler, J. S.; Culkin, D. J.; Walter, J. S.; Flanigan, R. C.; Urology
  • Role of surgery in metastatic renal cell carcinoma. Flanigan, R. C.; Seminars in urology
  • Colonic complications of renal transplantation. Flanigan, R. C.; Reckard, C. R.; Lucas, B. A.; The Journal of urology
  • The failure of infarction and/or nephrectomy in stage IV renal cell cancer to influence survival or metastatic regression. Flanigan, R. C.; The Urologic clinics of North America
888-584-7888

Dismiss Modal

Close 

Where would you like to share?